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Background and purpose: In randomized trials magnesium supplementation
did not improve clinical outcome after aneurysmal subarachnoid haemorrhage
(aSAH) on handicap scales. After aSAH, many patients have cognitive prob-
lems that may not translate into handicap. The eﬀect of magnesium on cogni-
tive outcome after aSAH was studied.
Methods: In total, 209 patients who had been included in the Magnesium for
Aneurysmal Subarachnoid Haemorrhage (MASH-2) trial in the UniversityMedi-
cal Centre of Utrecht were studied. Patients had been randomized to 64 mmol
magnesium sulfate daily or placebo during hospitalization. Three months after
aSAH patients underwent a neuropsychological examination (NPE) consisting of
six neuropsychological tests or a brief cognitive assessment. Poisson and linear
regression analyses were used to analyse the eﬀect of magnesium on cognition.
Results: In the magnesium group 53 (49.5%) of the 107 patients and in the
placebo group 51 (50.0%) of the 102 patients scored lower than the median
cognitive score [relative risk 0.99, 95% conﬁdence interval (CI) 0.76–1.30].
Linear regression analyses showed no signiﬁcant relationship between interven-
tion and cognition (B = 0.05, 95% CI 0.15 to 0.33).
Conclusions: Treatment with magnesium has no eﬀect on cognitive outcome
after aSAH.
Introduction
Despite positive results from preclinical and phase II
studies, large randomized clinical trials established
that treatment with magnesium does not improve clin-
ical outcome after aneurysmal subarachnoid haemor-
rhage (aSAH) [1,2]. The outcome in these trials was
assessed by means of handicap scales. However, cog-
nitive problems often hamper aSAH survivors and
may not be detected with handicap scales [3]. The aim
of this study was to assess the eﬀect of magnesium on
cognition after SAH.
Methods
Study design and patients
Patients admitted in the University Medical Centre of
Utrecht (UMCU) who had been included in the ran-
domized controlled trial Magnesium for Aneurysmal
Subarachnoid Haemorrhage (MASH-2, registered
ISRCTN 68742385, EudraCT 2006-003523-36) [1]
were studied. In the UMCU all patients discharged
home or to a rehabilitation institution are invited for
our routine outpatient clinic 3 months post-aSAH
including neuropsychological examination (NPE).
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Patients in whom the aneurysm was not proven by
computed tomography, magnetic resonance or con-
ventional angiography and patients with more than
30% missing tests on the NPE were excluded. A part
of the data in our study was derived from the MASH-
2 trial which complies with the Declaration of
Helsinki and good clinical practice guidelines. All
patients provided written and oral informed consent
for this trial. The use of the additional neuropsycho-
logical data in the present study was approved by the
UMCU Medical Ethics Committee. These data were
derived from a prospective data collection according
to clinical care as usual; therefore no additional
informed consent was used.
MASH-2
In the double-blinded MASH-2 study patients were
randomized to 64 mmol magnesium or a matching
placebo (saline) [1]. Treatment was started within
4 days after the aSAH and continued 20 days after
haemorrhage onset, or until hospital discharge or
death if it occurred sooner. Functional outcome was
measured by the modiﬁed Rankin Scale (mRS)
3 months after the aSAH.
Neuropsychological examination
Between November 2006 and August 2008, the NPE
consisted of six standard neuropsychological tests cov-
ering memory, attention, executive functioning and
visuospatial functioning. From September 2008 to
March 2011, the NPE protocol was changed into a
brief cognitive assessment. This assessment consisted of
18 items evaluating memory, language, attention, exec-
utive functioning, visuospatial functioning and orienta-
tion on a score ranging from 0 (unimpaired) to 2
(severely impaired). Overall cognitive functioning was
measured with a sum score of all 18 items. (More infor-
mation about both NPEs is presented in Data S1).
Analyses
Scores on both the NPE and the brief cognitive assess-
ment were transformed into z-scores based on means
and standard deviations of all patients per type of assess-
ment. The z-scores of the individual tests of the NPE
were summarized in a mean z-score to parallel the z-
score of the brief cognitive assessment. The mean z-
scores of both assessments were grouped into one overall
z-score. Cognition was analysed both as a continuous
(overall z-score) and dichotomous variable (di-
chotomized by the median of the overall z-score). The
eﬀect of magnesium was assessed by comparing patients
who received magnesium with those on placebo with lin-
ear and Poisson regression analyses. Moreover, a multi-
ple regression analysis was performed including
adjustments for other possible determinants of cognition
that changed the magnitude of the B (linear regression)
or relative risk (RR) (Poisson regression) by >5%. These
determinants were age, sex, educational level [using the
Dutch Verhage classiﬁcation system ranging from 1 (did
not complete primary school) to 7 (university degree)]
[4], clinical condition on admission measured with the
World Federation of Neurosurgeons SAH grading scale
[5], method of aneurysm treatment (clipping or endovas-
cular) and the neurological complications delayed cere-
bral ischaemia and hydrocephalus. Because there was
only one patient with aneurysmal rebleeding, this neuro-
logical complication was not included as a possible
determinant. After the multiple regression analyses, a
subgroup analysis was performed according to the type
of cognitive assessment.
Results
In total, 209 patients were included (Fig. 1); their
baseline characteristics are listed in Table 1. The mean
interval for the NPE was 12 weeks after aSAH.
Neuropsychological examination
Patients who performed the NPE did not diﬀer sub-
stantially from patients who completed the brief cogni-
tive assessment with respect to the distribution of the
intervention and the demographic and aSAH charac-
teristics (Table 1). For the distribution and median
split of the z-scores of both NPEs see Data S2.
Analyses
In the magnesium group 53 (49.5%) of the 107
patients and in the placebo group 51 (50.0%) of the
102 patients scored lower than the median cognitive
score (RR = 0.99, 95% CI 0.76–1.30). No signiﬁcant
relationship was found between magnesium and cog-
nition in the linear regression analyses (mean overall
z-scores: magnesium group 0.05, placebo group
0.04, B = 0.09, 95% CI 0.15 to 0.33). Upon
adjustment the RR estimate hardly changed whereas
B was inﬂuenced by age (B = 0.05, 95% CI 0.18 to
0.28), level of education (B = 0.08, 95% CI 0.16–
0.30), delayed cerebral ischaemia (B = 0.08, 95% CI
0.15 to 0.31) and hydrocephalus (B = 0.11, 95% CI
0.12– 0.35) yielding a multivariable estimate of 0.05,
96% CI 0.17 to 0.26. Subgroup analyses showed no
diﬀerences between the eﬀect of magnesium when ana-
lysing patients with an NPE (B = 0.06, 95% CI
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0.32 to 0.20; RR = 1.04, 95% CI 0.70–1.54) or the
brief cognitive assessment (B = 0.11, 95% CI 0.23 to
0.44; RR = 0.98; 95% CI 0.67–1.43).
Discussion
Magnesium does not inﬂuence cognitive outcome
after aSAH. To our knowledge this is the ﬁrst
study that used cognition as the outcome measure
in a randomized trial of magnesium in aSAH
patients. Patients were retrieved from the MASH-2
study [1], which is the largest randomized con-
trolled trial investigating magnesium in aSAH
patients to date. Not all patients of the MASH-2
trial met the inclusion criteria of the current study
but, given the criterion that patients had to be
Figure 1 Patient inclusion. MASH,
Magnesium for Aneurysmal Subarach-
noid Haemorrhage; UMCU, University
Medical Centre Utrecht; aSAH, aneurys-
mal subarachnoid haemorrhage; NPE,
neuropsychological examination. *Rea-
sons varied from being hospitalized, liv-
ing abroad to no-show. **Because of
visual problems, already performed NPE
elsewhere or patient’s refusal.
Table 1 Characteristics of aSAH patients (n = 209)
Magnesium (n = 107) Placebo (n = 102)
n % n %
Demographic characteristics
Women 84 79 81 79
Mean age in years (SD) 53.7 (11.7) 55.7 (11.5)
Educational level
Low–moderate (Verhage 1–5) 82 77 81 79
aSAH characteristics
WFNS
I–III, GCS 13–15 92 86 87 85
Aneurysm treatmenta
Clipping 45 42 45 44
Coiling 61 57 57 56
Neurological complications
Rebleeding 0 0 1 1
DCI 19 18 20 20
Hydrocephalus 21 20 16 16
Outcome 3 months after aSAH
Poor functional outcome
Slight/moderate disability (mRS 2) 45 42 46 45
Moderate/severe disability (mRS 4) 6 6 7 7
Cognitive outcome
Median (range) overall z-score 0.1 (3.0 to 1.3) 0.1 (3 to 1.2)
Overall z-score lower than median 53 50 51 50
aSAH, aneurysmal subarachnoid haemorrhage; DCI, delayed cerebral ischaemia; GCS, Glasgow coma score; mRS, modiﬁed Rankin Scale;
WFNS, World Federation of Neurosurgeons. aOne patient was not treated for a basilar top aneurysm because both posterior cerebral arteries
originated from this aneurysm and both carotid arteries were occluded.
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discharged home or to a rehabilitation institution,
a large study population with relatively good out-
come remained.
A limitation of our study is that two diﬀerent mea-
sures of cognitive outcome were used. Cognitive data
were derived from usual clinical care in which halfway
through the study period a change was made from a
formal NPE to a brief cognitive assessment. A sub-
group analysis, however, showed no diﬀerences
between the eﬀects of magnesium when analysing the
two measures of cognitive outcome separately.
Conclusions
This study shows that magnesium has no eﬀect on
cognitive outcome after aSAH.
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